Previous 10 | Next 10 |
Summary We believe the company's superior performance relative to other top healthcare equipment competitors is highlighted by its highest growth in Q3 2022. Following its acquisition, we believe the company's Labs segment has solid growth opportunities as it focuses on growing its immu...
Diagnostics technologies firm QuidelOrtho ( NASDAQ: QDEL ) expects Q4 revenues in the range of $853M to $868M vs. consensus estimate of $764.27M. COVID-19 product revenue is expected to be in the range of $124M-$134M and non-COVID-19 product revenue is expected to be in the ra...
QuidelOrtho to Report Fourth Quarter and Full Year 2022 Financial Results on February 15, 2023 QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of...
QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostics technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that members of its management team are scheduled to participate i...
Quidel TriageTrue hsTnl Test now available on smallest footprint analyzer QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicin...
Long-term partnership targets rapid assay development for local market needs QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho” or the “Company”), a global provider of innovative in vitro diagnostics (IVD) technologies designed for point-of-care settin...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes trading in ...
QuidelOrtho ( NASDAQ: QDEL ) Board of Directors has appointed Dr. Kenneth F. Buechler, lead independent director, to non-executive chairman, effective December 11, 2022. The separation of the chairman and CEO roles is a key step toward strengthening the company’s ...
Lead Independent Director Kenneth F. Buechler, PhD, appointed non-executive Chairman Douglas Bryant to continue as Chief Executive Officer and Director; Assumes role as President QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho” or the “Company”...
Citi raised its rating on QuidelOrtho Corporation ( NASDAQ: QDEL ) to Buy from Neutral on Monday, citing valuation as the reason for the upgrade at a time when the diagnostic product maker trades ~5% lower over the past three months. The analysts led by Patrick Donnelly compare Qu...
News, Short Squeeze, Breakout and More Instantly...
Avantor Set to Join S&P MidCap 400; QuidelOrtho & Schneider National to Join S&P SmallCap 600 Avantor Set to Join S&P MidCap 400; QuidelOrtho & Schneider National to Join S&P SmallCap 600 PR Newswire NEW YORK , July 23, 2024 /PRNewswir...
QuidelOrtho Corporation (Nasdaq: QDEL) (the “Company” or “QuidelOrtho”), a global provider of innovative in vitro diagnostic technologies designed for point-of-care settings, clinical labs and transfusion medicine, announced today that it will report its financ...
2024-07-09 04:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...